Table 2.
Information of primary antibodies used in the study.
| Antibody (Clone) | Company (Catalog Number) | Fixative | Concentration |
|---|---|---|---|
| Na+/K+-ATPase (0.T.1) | Santa Cruz (sc-71638) | 100% Ethanol 5 minutes, 4 °C | 5 µg/mL |
| ZO-1 (1/ZO-1) | BD Pharmingen (610966) | 100% Ethanol 5 minutes, 4 °C | 5 µg/mL |
| CD-166 (TAG-1A3) | In-house29 | 100% Ethanol 5 minutes, 4 °C | Supernatant |
| PRDX-6 (TAG-2A12) | In-house29 | Fix and Perm (Medium A) 15 minutes, room temp. | Supernatant |
| Human Nuclei (235-1) | Merck (Chemicon) (MAB1281) | 4% Paraformaldehyde 10 minutes, 4 °C | 1:100 dilution |
The three commercially available primary antibodies used in this study, Na+/K+-ATPase, ZO-1 and Human Nuclei are listed here by their clone name, the company of which the primary antibody was purchased from, with their respective catalog numbers. Both CD-166 (TAG-1A3) and PRDX-6 (TAG-2A12) are generated in-house as described29. The different methods of fixation and concentration used were optimized for the staining of primary human CEnCs.